× Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our privacy policy



meta|IO

Living evidence synthesis
about Immuno-Oncology drugs

Member of the meta|Evidence galaxy

Pathology  

Latest studies

DESTINY-Breast04, 2022

metastatic/advanced - breast cancer (mBC)

trastuzumab deruxtecan

NCT00454805, 2013

breast cancer - HR positive

cediranib plus fulvestrant

NEO-ORB (mutant cohort), 2019

breast cancer - HR positive

alpelisib plus letrozole

NCT02756364 (sapanisertib weekly), 2022

breast cancer - HR positive

sapanisertib plus fulvestrant

Treatments

427
treatments 		  303
studies 		  1080
references
This project is supported by H2020 Qualitop, an EU-funded project, Hospices Civils de Lyon and CNRS UMR5558 LBBE.
     

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons